Approved indication fi elds for new drugs form the basis of numerous drug pricing processes in Europe, also in Germany. Diff erences between drugs in overlapping indications over time can cause problems of comparability. The aim of this analysis is the systematic collection of indication fi elds in German prescribing information over time and the linkage with existing evidence for approval. Questions to be answered include how indication fi elds develop over time, whether there are specifi cations or generalizations and if these are adequately covered by approval evidence, i.e. submitted trials?
Objectives
Approved indication fi elds for new drugs form the basis of numerous drug pricing processes in Europe, also in Germany. Diff erences between drugs in overlapping indications over time can cause problems of comparability. The aim of this analysis is the systematic collection of indication fi elds in German prescribing information over time and the linkage with existing evidence for approval. Questions to be answered include how indication fi elds develop over time, whether there are specifi cations or generalizations and if these are adequately covered by approval evidence, i.e. submitted trials?
Methods
The German "Rote Liste" and "Fachinfo" was searched from 19-FEB to 9-MAR-2018 for current prescribing information. The search was limited to the following diseases: Acute coronary syndrome, chronic obstructive pulmonary disease (COPD), diabetes, epilepsy, multiple sclerosis (MS), hepatitis, human immunodefi ciency virus (HIV), melanoma, lung/prostate/breast cancer [1] [2] . Indication fi elds and years of approval were extracted. Indication fi elds were compared for drugs within one indication. If changes in indication fi elds were detected, it was checked whether approval evidence supported these developments (taken from European Public Assessment Reports) [3] .
Conclusions
Indication fi elds develop over time and are partially not completely supported by underlying approval evidence. Between-drug-comparability within one indication could also be enhanced. Missing evidence and between-drug-diff erences pose a challenge for drug pricing processes, not only in Germany.
As to approval evidence, especially diabetes mellitus type-2 drugs were approved for indications not completely supported by submitted clinical trials. Since 2007 a stronger focus has been placed on drugs without insulin, mainly dipeptidyl peptidase-4 inhibitor (DPP4) and glucagon-like peptide-1 agonists (GLP1) (Fig. 2) . Moreover patient-oriented therapies were aimed at, e.g. for patients with contraindications or intolerances to other antidiabetics ( Fig. 3 ).
For instance dulaglutide is approved as monotherapy for patients with a contraindication or intolerance to metformin. According to the European Public Assessment Report (EPAR), these patients were excluded in the clinical trials submitted, which were combination trials with metformin mainly [4] .
Results 2 -Linkage with existing evidence for approval [ formulations. In the indication fi eld breast cancer diff erent degrees in severity of disease caused diff erences, exemplary. The most frequent disease severity was metastatic breast cancer (49,3%), followed by locally advanced breast cancer (18,3%) ( Fig. 1) . 
Results 1 -Systematic collection of indiciation fi elds and common diff erences

